Stocktoria
ENANTA PHARMACEUTICALS INC ENTA
ENANTA PHARMACEUTICALS INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.3M | $67.6M | $79.2M | $86.2M | $97.1M | $122.5M | $205.2M | $206.6M | $102.8M | $88.3M |
| R&D expense | $106.7M | $131.5M | $163.5M | $164.5M | $174.1M | $136.8M | $142.2M | $94.9M | $57.5M | $40.5M |
| Operating income | -$85.3M | -$121.7M | -$137.2M | -$123.8M | -$109.6M | -$41.6M | $36.7M | $88.3M | $24.6M | $30.8M |
| Interest expense | — | — | $5.1M | $0 | $0 | — | — | — | $40,000 | $45,000 |
| Income tax | -$1.7M | -$1.7M | $2.8M | -$433,000 | -$28.6M | $1.1M | -$826,000 | $21.2M | $9.2M | $10.9M |
| Net income | -$81.9M | -$116.0M | -$133.8M | -$121.8M | -$79.0M | -$36.2M | $46.4M | $72.0M | $17.7M | $21.7M |
| EPS (diluted) | $-3.84 | $-5.48 | $-6.38 | $-5.91 | $-3.92 | $-1.81 | $2.21 | $3.48 | $0.91 | $1.13 |
| Operating cash flow | -$19.3M | -$78.8M | -$103.2M | -$84.8M | -$70.0M | $7.1M | $71.4M | $29.2M | $52.7M | $35.8M |
| Free cash flow | -$32.2M | -$96.7M | -$112.2M | -$86.9M | -$70.7M | $5.6M | $66.0M | $26.2M | $50.1M | $31.1M |
| Cash & equivalents | $32.3M | $37.2M | $85.4M | $44.0M | $57.2M | $87.1M | $51.2M | $63.9M | $65.7M | $16.6M |
| Total assets | $280.7M | $376.7M | $462.3M | $375.4M | $438.8M | $486.1M | $489.8M | $414.2M | $326.6M | $281.3M |
| Total liabilities | $216.0M | $247.8M | $245.5M | $54.1M | $39.4M | $30.6M | $27.3M | $20.5M | $25.0M | $11.3M |
| Shareholders' equity | $64.7M | $128.8M | $216.7M | $321.3M | $399.4M | $455.6M | $462.5M | $393.7M | $301.7M | $269.9M |
Growth · year-over-year · Revenue CAGR -3.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -3.4% | -14.6% | -8.1% | -11.2% | -20.7% | -40.3% | -0.7% | +101.0% | +16.5% | -45.1% |
| Net income growth | — | — | — | — | — | -178.0% | -35.5% | +306.3% | -18.3% | -72.6% |
| EPS growth | — | — | — | — | — | -181.9% | -36.5% | +282.4% | -19.5% | -72.4% |
| Free cash flow growth | — | — | — | — | -1353.7% | -91.5% | +151.5% | -47.7% | +61.4% | -58.2% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.